arrow
R

Roland Penzel

Ruprecht Karls University Heidelberg
H指数:54
被引数:8,486

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
2022-11-0128
OA
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly- informed therapies despite heterogeneity
2022-08-0227
OAAI
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

EGFR-和ERBB2-mutated肺腺癌的免疫微环境

2021-10-0123
OAAI
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

将证据分配给可操作性: 精准癌症医学中的变异解释简介

2021-08-0916
OAAI
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
2021-06-259
OAAI
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

全面的基因组和转录组学分析可指导罕见癌症患者的治疗决策

2021-06-10150
OA
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas
2021-03-1616
PRE
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
2019-07-010
PRE
Variant classification in precision oncology
2019-05-2180
OAAI
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
2019-04-0956
OAAI
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
2019-02-1988
OAAI
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
2019-02-0493
OAAI
Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study
2018-10-1712
OAAI